Weifa ASA is proud to announce the launch of Bronkyl forte 600 mg effervescent
tablets, a new line extension to the already well established Bronkyl 200 mg.
Bronkyl 200 mg is as per today the 6(th) most sold OTC product in Norway. The
addition of a new 600 mg line extension is expected to strengthen further the
brand.

"Our ambition for the Bronkyl brand is to become market leader within the OTC
cough segment (measured by value) in Norway. The launch of Bronkyl forte,
combined with a strong pipeline, is another step towards achieving our goal to
be the fastest growing company in the Cough & Cold category in Norway" says CEO
Kathrine Gamborg Andreassen in Weifa ASA.

Bronkyl forte contains acetylcysteine which is a mucolytic agent helping clear
your chest from unwanted mucus. This new 600 mg strength makes it possible to
have a dosage of only one effervescent tablet per day.

From 15 September 2015, Bronkyl forte in 10 tablets package will be available
without prescription in all pharmacies in Norway. The launch will be supported
by a solid communication campaign both towards the end user and the medical
staff.

 

Further information from:

Kathrine Gamborg Andreassen
CEO
+47 95 17 86 80
kathrine.gamborg.andreassen@weifa.no

Simen Nyberg-Hansen
CFO
+47 98 20 63 55
simen.nyberg-hansen@weifa.no

 

Weifa is Norway's leading consumer health company. We supply real value through
medicines, lifestyle products and solutions that address the essential needs of
consumers, customers and professional partners. Weifa was founded in 1940 and
now employs about 30 highly qualified people at our headquarters in Oslo. The
company has a strong position in Norway and is the market leader in pain relief,
with well-established brands such as Paracet and Ibux. We are also present in
other key areas such as dietary supplements and treatment for colds and
respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For
further information, please visit: www.weifa.no


This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.